Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
9.09
-0.27 (-2.88%)
Mar 19, 2026, 4:00 PM EDT - Market closed
Rallybio Employees
Rallybio had 15 employees as of September 30, 2025. The number of employees decreased by 10 or -40.00% compared to the same quarter last year.
Employees
15
Change
-10
Growth
-40.00%
Revenue / Employee
$57,200
Profits / Employee
-$598,533
Market Cap
48.08M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 15 | -10 | -40.00% |
| Jun 30, 2025 | 20 | -5 | -20.00% |
| Mar 31, 2025 | 24 | -6 | -20.00% |
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Sep 30, 2024 | 25 | -19 | -43.18% |
| Jun 30, 2024 | 25 | -20 | -44.44% |
| Mar 31, 2024 | 30 | -13 | -30.23% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Sep 30, 2023 | 44 | 0 | - |
| Jun 30, 2023 | 45 | 0 | - |
| Mar 31, 2023 | 43 | 3 | 7.50% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Sep 30, 2022 | 44 | 13 | 41.94% |
| Jun 30, 2022 | 45 | 17 | 60.71% |
| Mar 31, 2022 | 40 | 12 | 42.86% |
| Dec 31, 2021 | 35 | 7 | 25.00% |
| Sep 30, 2021 | 31 | - | - |
| Jun 30, 2021 | 28 | - | - |
| Mar 31, 2021 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| ImmuCell | 84 |
| Acrivon Therapeutics | 78 |
| Kezar Life Sciences | 55 |
| GeoVax Labs | 17 |
| Atossa Therapeutics | 15 |
| OS Therapies | 5 |
| Decoy Therapeutics | 2 |
RLYB News
- 17 days ago - Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
- 18 days ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
- 4 weeks ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 4 weeks ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 6 weeks ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 4 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 6 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire